Resmetirom is a thyroid hormone receptor-beta (THR-β) agonist that was licensed by the U.S. Food and Drug Administration in March 2024 exclusively for the treatment of MASH (25). This evidence concerns the gene THRB and metabolic dysfunction-associated steatohepatitis.